Claims second shot increases protection 13 percentage points.
On Tuesday, Johnson & Johnson requested the Food and Drug Administration (FDA) to approve additional use of its COVID-19 vaccine for booster shots. The authorization would be for adults who are 18 years or older who previously received the company’s one-shot vaccine. The FDA recently approved the use of Pfizer’s vaccine for booster shots for those at-risk of the virus.
Recent data from J&J has shown that its vaccine is effective against COVID-19 for at least five months after vaccination, and with an 81% effectiveness against being hospitalized if contracting the disease. Company data also showed that receiving a booster shot either two or six months after the first dose increased protection to 94%.
As the Lord Leads, Pray with Us…
- For officials of the FDA as they study the efficacy of treatments.
- For Secretary Becerra to seek God’s guidance as he heads the HHS department.
- For wisdom for Director Walensky as she issues CDC recommendations.
- For state and local government leaders to have wisdom in implementing COVID-19 mitigation measures.
Sources: AP, Reuters
